ImmunoCellular Therapeutics Культура компании

Dr. Steven J. Swanson, also known as Steve, M.D., Ph.D. has been a Senior Vice President of Research at ImmunoCellular Therapeutics, Ltd. since February 2015. Prior to joining ImmunoCellular, Dr. Swanson served as an independent consultant advising biopharmaceutical companies on basic immunology research, bioanalytical procedures, immunogenicity assessment, regulatory affairs and product quality. Dr. Swanson spent 15 years at Amgen as Department Head for Clinical Immunology, a then-new department providing immunogenicity and cytometry support for all of Amgen's therapeutic proteins. Prior to joining Amgen, he led the immunoassay laboratory in the Biotechnology department at Schering Plough Research Institute. Dr. Swanson has been actively involved in multiple industry professional associations, including the American Association of Pharmaceutical Scientists (AAPS), where he is a Fellow and was a co-author of AAPS-sponsored Industry White Papers that were incorporated into FDA and EMA Guidance for Immunogenicity Assessment. He was also an industry representative for the EMA Committee that developed the first Immunogenicity Recommendations and was engaged by the FDA to train reviewers on immunogenicity assessment. Dr. Swanson has authored more than 60 publications. He holds a BA in chemistry/biology from North Central College, a PhD in microbiology from the University of Iowa and completed a post-doctoral fellowship at The Ohio State University.

Mr. Gary S. Titus, CPA has been Chief Financial Officer of UroGen Pharmaceuticals, Ltd. since July 2015. Mr. Titus has been Company Secretary of ImmunoCellular Therapeutics, Ltd. since September 2015. He served as the Chief Financial Officer of BioCardia, Inc since May 2014 until October 20, 2015. He served as the Chief Financial Officer and Senior Vice President of Finance at SciClone Pharmaceuticals, Inc. from December 8, 2008 to May 31, 2013 and served as its Principal Accounting Officer until May 31, 2013. He has biotechnology industry and healthcare sectors experience to lead finance activities and investor relations, as well as oversaw human resources and legal affairs of SciClone Pharmaceuticals Inc. Mr. Titus served as the Chief Financial Officer, Principal Accounting Officer and Senior Vice President of Kosan Biosciences Incorporated from August 15, 2006 to September 2008. He was responsible for SEC reporting and audit, compliance, treasury and finance as well as financial analysis and planning of Kosan Biosciences Incorporated. He plays a key role in managing Kosan Biosciences Incorporated's relationships with investors, bankers and other external stakeholders. He is an accomplished financial executive with more than 20 years of senior financial management experience focused largely on the biotechnology and healthcare industries. Mr. Titus served as an Acting Chief Financial Officer at Nuvelo Inc from November 2005 to July 2006. He joined Nuvelo, Inc. in January 2003. He served as the Chief Accounting Officer and Vice President of Finance of Nuvelo Inc., from July 23, 2004 to September 1, 2006. He led several successful financings and represented in the investment community. Prior to Nuvelo, he served as a senior finance positions at emerging life science companies including Metabolex Inc., and IntraBiotics Pharmaceuticals Inc. In addition, Mr. Titus held a variety of financial management positions at LifeScan Inc., a division of Johnson & Johnson Inc. He has been Chairman and Director of ImmunoCellular Therapeutics, Ltd., since September 2015 and January 2, 2013 respectively. He holds a Bachelor of Science degree in Finance from the University of Florida and a Bachelor of Science degree in Accounting from the University of South Florida and is a Certified Public Accountant. Mr. Titus completed the Global BioExecutive Program at UC Berkeley's Haas School of Business and is a Member of several professional organizations.

Dr. John S. Yu, M.D., Ph.D., Founded ImmunoCellular Therapeutics, Ltd. Dr. Yu serves as Director of Surgical Neurooncology, Director of Gamma Knife, full-time faculty and Co-Director of Comprehensive Brain Tumor Program for Department of Neurosurgery at Cedars-Sinai Medical Center. Dr. Yu served as Consultant of ImmunoCellular Therapeutics, Ltd. since October 1, 2015 until September 8, 2017. He served as Chief Scientific Officer of ImmunoCellular Therapeutics, Ltd. from November 2006 to October 1, 2015. He served as an Interim Chief Executive Officer and Interim President of ImmunoCellular Therapeutics Ltd., from August 2012 to December 3, 2012. Dr. Yu served as the Chief Scientific Officer of ImmunoCellular Therapeutics, Ltd. (formerly, Optical Molecular Imaging, Inc.) from September 2006 to January 2007 and served as its Corporate Secretary. An internationally renowned neurosurgeon, his clinical focus is on the treatment of malignant and benign brain and spinal tumors. He is also conducting extensive research in immune and gene therapy for brain tumors. He serves as principal investigator for immunotherapy trials conducted at Cedars-Sinai. He has also done extensive research in the use of neural stem cells as delivery vehicles for brain cancers and neurodegenerative diseases. Dr. Yu served as the Chairman at ImmunoCellular Therapeutics, Ltd. since January 23, 2007 and has been its Director since November 2006. He has published articles in a number of prestigious journals, including The Lancet, Cancer Research, Cancer Gene Therapy, Human Gene Therapy, Journal of Neuro Immunology, Journal of Neurological Science and Journal of Neurosurgery. Dr. Yu was a Neuroscience Fellow at the National Institutes of Mental Health in the Neuro Immunology Unit at Massachusetts General Hospital from 1988 to 1989 and was Culpepper Scholar at the Molecular Neurogenesis Unit at that hospital from 1993 to 1995. Dr. Yu was inducted into Castle and Connelly's America's Top Doctors in 2005. His other honors include the Preuss Award, Joint Section on Tumors, American Association of Neurological Surgeons and Congress of Neurologic Surgeons in 1995. Dr. Yu received the Academy Award from American Academy of Neurological Surgery at its 1996 annual meeting. Other honors include the Young Investigator Award from the Congress of Neurological Surgeons in 2000, the National Brain Tumor Foundation Grant in 2001 and the Mahaley Clinical Research award from American Association of Neurological Surgeons in 2005. He Completed his Neurosurgical residency at Massachusetts General Hospital in Boston. Dr. Yu earned his bachelor's degree in French Literature and Biological Sciences from Stanford University and spent a year at the Sorbonne in Paris studying French Literature. He earned his Medical Degree from Harvard Medical School and Master's Degree from Harvard University's Department of Genetics.

Mr. David E. Fractor, CPA, has been Chief Financial Officer of ImmunoCellular Therapeutics, Ltd. since April 14, 2017. Mr. Fractor serves as the Chief Financial Officer of Hemo Therapeutics, Inc. Since 2003, he has been a Consultant providing financial consulting and strategic planning services, including Sarbanes-Oxley compliance consulting services. He served as the Chief Financial Officer and Treasurer of ImmunoCellular Therapeutics, Ltd. from April 2011 to March 2013 and as its Principal Accounting Officer and Vice President of Finance from March 2013 to April 2017. Mr. Fractor served as the Chief Financial Officer of iDcentrix Inc. from February 15, 2008 to October 21, 2009, Treasurer from April 15, 2008 to October 21, 2009 and as its Principal Accounting Officer until October 21, 2009. Mr. Fractor served as the Chief Financial Officer of Pheresys Therapeutics Corporation. From June 1999 to 2003, he served as the Chief Financial Officer of HemaCare Corporation. Prior to HemaCare, he served as Chief Financial Officer of Andwin Corporation since 1996. From 1994 to 1996, Mr. Fractor performed consulting services, primarily functioning as interim Chief Financial Officer for emerging public companies. From 1986 to 1994, he served as an Audit Manager at both Deloitte and Touche and Weber, Lipshie & Co., a regional accounting firm. He served as Director of iDcentrix, Inc. until October 21, 2009. He is a Certified Public Accountant and a Member of AICPA and the California Society of CPA's. Mr. Fractor received his B.S. in Accounting from the University of Southern California in 1982.

Steven Swanson serves as the Senior Vice President, Research of ImmunoCellular Therapeutics Ltd. Steven started at ImmunoCellular Therapeutics Ltd in February of 2015. Steven currently resides in Greater Los Angeles Area.